Nothing Special   »   [go: up one dir, main page]

BR112022025675A2 - Método para determinar antígeno livre - Google Patents

Método para determinar antígeno livre

Info

Publication number
BR112022025675A2
BR112022025675A2 BR112022025675A BR112022025675A BR112022025675A2 BR 112022025675 A2 BR112022025675 A2 BR 112022025675A2 BR 112022025675 A BR112022025675 A BR 112022025675A BR 112022025675 A BR112022025675 A BR 112022025675A BR 112022025675 A2 BR112022025675 A2 BR 112022025675A2
Authority
BR
Brazil
Prior art keywords
antibody
antigen
tracer
epitope
capture
Prior art date
Application number
BR112022025675A
Other languages
English (en)
Inventor
Jordan Gregor
Schaefer Martin
Viert Maria
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112022025675A2 publication Critical patent/BR112022025675A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

MÉTODO PARA DETERMINAR ANTÍGENO LIVRE. A presente invenção trata de um método para determinar o antígeno livre de um anticorpo em uma amostra de soro não diluído que compreende as etapas de (a) aplicar a amostra não diluída a uma fase sólida na qual um anticorpo de captura foi imobilizado para formar um complexo anticorpo de captura-antígeno, em que o anticorpo de captura compete com o anticorpo pela ligação a um primeiro epítopo no antígeno, (b) aplicar à fase sólida de um anticorpo traçador para formar um complexo anticorpo de captura-antígeno-anticorpo traçador, em que o anticorpo traçador se liga especificamente a um segundo epítopo em o antígeno, em que o epítopo do anticorpo traçador não se sobrepõe ao epítopo do anticorpo de captura no antígeno, e (c) determinar o antígeno livre do anticorpo ao determinar o anticorpo traçador no complexo anticorpo de captura-antígeno-anticorpo traçador.
BR112022025675A 2020-06-16 2021-06-14 Método para determinar antígeno livre BR112022025675A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20180205 2020-06-16
PCT/EP2021/065880 WO2021254926A1 (en) 2020-06-16 2021-06-14 Method for determining the free antigen of an antibody in a sample

Publications (1)

Publication Number Publication Date
BR112022025675A2 true BR112022025675A2 (pt) 2023-03-07

Family

ID=71103268

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025675A BR112022025675A2 (pt) 2020-06-16 2021-06-14 Método para determinar antígeno livre

Country Status (11)

Country Link
US (1) US20230393125A1 (pt)
EP (1) EP4165409A1 (pt)
JP (1) JP2023530977A (pt)
KR (1) KR20230017308A (pt)
CN (1) CN115917320A (pt)
AU (1) AU2021294222A1 (pt)
BR (1) BR112022025675A2 (pt)
CA (1) CA3183441A1 (pt)
IL (1) IL298923A (pt)
MX (1) MX2022015899A (pt)
WO (1) WO2021254926A1 (pt)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
EP0757252A3 (en) 1988-11-03 1997-04-16 Igen Inc Electrochemiluminescent test procedure
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
WO2002030886A2 (en) 2000-10-12 2002-04-18 Matthews Barry R Heterocyclic angiogenesis inhibitors
BRPI0211953B8 (pt) 2001-08-17 2021-05-25 Genentech Inc anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
FR2842069B1 (fr) 2002-07-12 2004-09-10 Pellenc Sa Effeuilleuse, plus specialement destinee a l'effeuillage selectif de la vigne
US20050148975A1 (en) 2003-12-31 2005-07-07 Kimberly-Clark Worldwide, Inc. Disposable garment having an elastic inner layer with a narrow width in the crotch region
WO2007096586A1 (en) 2006-02-20 2007-08-30 Pepperl & Fuchs (De) Fieldbus physical layer diagnostics data conversion device
WO2008060790A2 (en) 2006-10-13 2008-05-22 Ochsner Clinic Foundation Detection of ckd or cad using bmp-4
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
DK2894165T5 (da) 2008-11-10 2024-10-14 Alexion Pharma Inc Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
MX2011010159A (es) 2009-04-02 2011-10-17 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
RU2570633C2 (ru) 2009-05-27 2015-12-10 Ф.Хоффманн-Ля Рош Аг Три- или тетраспецифические антитела
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
US20150168396A1 (en) 2012-08-08 2015-06-18 Hoffmann-La Roche Inc. Immunoassay-based determination of in-solution binding kinetics
DK3122461T3 (da) 2014-03-28 2020-03-23 Curiosity Diagnostics Sp Z O O Indretning til samtidig og ensartet termisk cyklus af prøver og anvendelser deraf
US11965884B2 (en) 2016-10-19 2024-04-23 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5 in a sample

Also Published As

Publication number Publication date
EP4165409A1 (en) 2023-04-19
JP2023530977A (ja) 2023-07-20
WO2021254926A1 (en) 2021-12-23
KR20230017308A (ko) 2023-02-03
MX2022015899A (es) 2023-01-24
AU2021294222A1 (en) 2023-01-19
CN115917320A (zh) 2023-04-04
CA3183441A1 (en) 2021-12-23
IL298923A (en) 2023-02-01
US20230393125A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
Reyes et al. Four monoclonal antibodies against capsular polysaccharides of Neisseria meningitidis serogroups A, C, Y and W135: its application in identity tests
BR112022013545A2 (pt) Anticorpos anti-tigit e método de uso
ATE236398T1 (de) Verbessertes verfahren zum nachweis von säure- resistenten bakterien der gattung helicobacter im stuhl
RU2016107435A (ru) Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
BR112021026089A2 (pt) Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos
Palmieri et al. Development of an analytical protocol for a fast, sensitive and specific protein recognition in paintings by enzyme-linked immunosorbent assay (ELISA)
BR112022011669A2 (pt) Anticorpos biespecíficos caninizados e parceiros de ligação biespecíficos para tratar dermatite atópica
BR112023003511A2 (pt) Anticorpo biespecífico calr-cd3 mutante anticlivado e composição farmacêutica
BR112022008730A2 (pt) Epítopo de antígeno de superfície de células t reguladoras e um anticorpo que se liga especificamente ao mesmo
Stanker et al. A double-sandwich ELISA for identification of monoclonal antibodies suitable for sandwich immunoassays
JP2019015736A5 (pt)
JP7455947B2 (ja) アデノウイルスの免疫測定方法及び免疫測定器具
RU2015107740A (ru) Способ измерения, реагент для измерения и набор для измерения pivka-ii
BR112022025675A2 (pt) Método para determinar antígeno livre
CL2023000595A1 (es) Anticuerpo que se une a vegf-a y ang2, y métodos de uso
HRP20171623T1 (hr) Poboljšana cjepivna dijagnostika
BR112022002376A2 (pt) Anticorpos que se ligam especificamente à troponina t cardíaca humana, anticorpos, moléculas de ácido nucleico, vetor, composição e método para determinar a troponina t cardíaca humana
Riches-Duit et al. Characterisation of diphtheria monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay
BR112023016713A2 (pt) Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
KR880013013A (ko) 액체 샘플내 다가 항원의 정량시약 및 면역화학적 정량방법
BR112022004570A2 (pt) Terapia de combinação com anticorpos entpd2 e cd73
Manouvriez Use of anti-rat kappa light chain allotype monoclonal antibodies for the quantification of rat monoclonal antibodies in ascitic fluid or serum
WO2016194797A1 (ja) 被検対象の検出方法並びにそのための免疫測定器具及びモノクローナル抗体
BR112019004025A2 (pt) métodos para identificação de epítopos
BR112022024161A2 (pt) Anticorpo multiespecífico, sequência de ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo multiespecífico e composição farmacêutica